Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Comergent Technologies Inc.: Enterprise E-Commerce, Teaching Note
Rangan, V. Kasturi; Bellfor, MarieNota del Instructor HBS-507087-EMarketingTeaching Note to (505-016). An abstract is not available for this product.Desde 0,00 €
-
FreeMarkets OnLine (Spanish Version)
Rangan, V. KasturiCaso HBS-502S16MarketingDescribe la estrategia de marketing de una puesta en marcha empresarial dedicada a la compra electrónica para los grandes fabricantes. Al crear una plataforma de licitación electrónica, la compañía ha sido capaz de reducir los costos de adquisición en un 15%. La pregunta trata de casos como esta empresa debe ir ahora a escala.Desde 8,20 €
-
Gilead: Hepatitis-C Access Strategy (A)
Rangan, V. Kasturi; Rangan, Vikram; Bloom, David E.Caso HBS-515025-EGilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of thi...Desde 8,20 €
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCaso HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Desde 8,20 €
-
Rosetta Stone: Pricing the 2009 IPO
Schill, Michael J.; Papireddy, Suprajj; Adams, Tom; Clough, PhilCaso DARDEN-F-1613-EFinanzasThis case examines the April 2009 decision of Rosetta Stone management to price the initial public offering of Rosetta Stone stock during one of the most difficult periods in capital-raising history. The case outlines Rosetta Stone’s unique language learning strategy and the associated strong financial performance. Students are invited to value the stock and take a position on whether the current $15 to $17 per share filing range is appropriate. ...Desde 8,20 €
-
Fonderia del Piemonte S.p.A - Teaching Note
Bruner, Robert F.; Schill, Michael J.Nota del Instructor DARDEN-F-1764TN-EFinanzasTeaching note for product F-1764Desde 0,00 €
-
Shamrock Capital: Pricing the Masters of Taylor Swift
Schill, Michael J.Caso DARDEN-F-2050-EFinanzasThis case examines the 2020 pricing decision for the master recordings of Taylor Swift’s first six albums in consideration of a sale of the recordings by music executive Scooter Braun to Shamrock Capital (Shamrock), an investment company owned by the Roy E. Disney family. Swift, the most listened-to musician in the world, had expressed displeasure with Braun’s ownership of her masters and a desire to own the recordings herself—even threatening to...Desde 8,20 €
-
Goldman Sachs: The 10,000 Women Initiative, Teaching Note
Marquis, Christopher; Rangan, V. Kasturi; Thomason, BobbiNota del Instructor HBS-410119-ETeaching Note for [509042].Desde 0,00 €
-
American Greetings - Teaching Note
Schill, Michael J.Nota del Instructor DARDEN-F-1693TN-EFinanzasTeaching note for product F-1693Desde 0,00 €
-
Carter International - Teaching Note
Schill, Michael J.Nota del Instructor DARDEN-F-1771TN-EFinanzasTeaching note for product F-1771Desde 0,00 €